Artificial Intelligence (AI) and infectious diseases prediction have recently experienced a common development and advancement. Machine learning (ML) apparition, along with deep learning (DL) emergence, extended many approaches against diseases apparition and their spread. And despite their outstanding results in predicting infectious diseases, conflicts appeared regarding the types of data used and how they can be studied, analyzed, and exploited using various emerging methods. This has led to some ongoing discussions in the field. This research aims not only to provide an overview of what has been accomplished, but also to highlight the difficulties related to the types of data used, and the learning methods applied for each research objective. It categorizes these contributions into three areas: predictions using Public Health Data to prevent the spread of a transmissible disease within a region; predictions using Patients' Medical Data to detect whether a person is infected by a transmissible disease; and predictions using both Public and patient medical data to estimate the extent of disease spread in a population. The paper also critically assesses the potential of AI and outlines its limitations in infectious disease management.

The Reverse Transcription Polymerase Chain Reaction (RTPCR) test is the silver bullet diagnostic test to discern COVID infection. Rapid antigen detection is a screening test to identify COVID positive patients in little as 15 minutes, but has a lower sensitivity than the PCR tests. Besides having multiple standardized test kits, many people are getting infected & either recovering or dying even before the test due to the shortage and cost of kits, lack of indispensable specialists and labs, time-consuming result compared to bulk population especially in developing and underdeveloped countries. Intrigued by the parametric deviations in immunological & hematological profile of a COVID patient, this research work leveraged the concept of COVID-19 detection by proposing a risk-free and highly accurate Stacked Ensemble Machine Learning model to identify a COVID patient from communally available-widespread-cheap routine blood tests which gives a promising accuracy, precision, recall & F1-score of 100%. Analysis from R-curve also shows the preciseness of the risk-free model to be implemented. The proposed method has the potential for large scale ubiquitous low-cost screening application. This can add an extra layer of protection in keeping the number of infected cases to a minimum and control the pandemic by identifying asymptomatic or pre-symptomatic people early.

Physicians taking care of patients with COVID-19 have described different changes in routine blood parameters. However, these changes hinder them from performing COVID-19 diagnoses. We constructed a machine learning model for COVID-19 diagnosis that was based and cross-validated on the routine blood tests of 5333 patients with various bacterial and viral infections, and 160 COVID-19-positive patients. We selected the operational ROC point at a sensitivity of 81.9% and a specificity of 97.9%. The cross-validated AUC was 0.97. The five most useful routine blood parameters for COVID-19 diagnosis according to the feature importance scoring of the XGBoost algorithm were: MCHC, eosinophil count, albumin, INR, and prothrombin activity percentage. t-SNE visualization showed that the blood parameters of the patients with a severe COVID-19 course are more like the parameters of a bacterial than a viral infection. The reported diagnostic accuracy is at least comparable and probably complementary to RT-PCR and chest CT studies. Patients with fever, cough, myalgia, and other symptoms can now have initial routine blood tests assessed by our diagnostic tool. All patients with a positive COVID-19 prediction would then undergo standard RT-PCR studies to confirm the diagnosis. We believe that our results represent a significant contribution to improvements in COVID-19 diagnosis.

Physicians taking care of patients with coronavirus disease (COVID-19) have described different changes in routine blood parameters. However, these changes, hinder them from performing COVID-19 diagnosis. We constructed a machine learning predictive model for COVID-19 diagnosis. The model was based and cross-validated on the routine blood tests of 5,333 patients with various bacterial and viral infections, and 160 COVID-19-positive patients. We selected operational ROC point at a sensitivity of 81.9% and specificity of 97.9%. The cross-validated area under the curve (AUC) was 0.97. The five most useful routine blood parameters for COVID19 diagnosis according to the feature importance scoring of the XGBoost algorithm were MCHC, eosinophil count, albumin, INR, and prothrombin activity percentage. tSNE visualization showed that the blood parameters of the patients with severe COVID-19 course are more like the parameters of bacterial than viral infection. The reported diagnostic accuracy is at least comparable and probably complementary to RT-PCR and chest CT studies. Patients with fever, cough, myalgia, and other symptoms can now have initial routine blood tests assessed by our diagnostic tool. All patients with a positive COVID-19 prediction would then undergo standard RT-PCR studies to confirm the diagnosis. We believe that our results present a significant contribution to improvements in COVID-19 diagnosis.

The COVID-19 is sweeping the world with deadly consequences. Its contagious nature and clinical similarity to other pneumonias make separating subjects contracted with COVID-19 and non-COVID-19 viral pneumonia a priority and a challenge. However, COVID-19 testing has been greatly limited by the availability and cost of existing methods, even in developed countries like the US. Intrigued by the wide availability of routine blood tests, we propose to leverage them for COVID-19 testing using the power of machine learning. Two proven-robust machine learning model families, random forests (RFs) and support vector machines (SVMs), are employed to tackle the challenge. Trained on blood data from 208 moderate COVID-19 subjects and 86 subjects with non-COVID-19 moderate viral pneumonia, the best result is obtained in an SVM-based classifier with an accuracy of 84%, a sensitivity of 88%, a specificity of 80%, and a precision of 92%. The results are found explainable from both machine learning and medical perspectives. A privacy-protected web portal is set up to help medical personnel in their practice and the trained models are released for developers to further build other applications. We hope our results can help the world fight this pandemic and welcome clinical verification of our approach on larger populations.

In literature, characters that smoke are often described as haggard and older looking, with facial features that are associated with worn leather. While these depictions arguably carry over into reality, what is for certain is that the association between smoking, cancer, and cardiovascular disease is strong. Unfortunately, however, the connection between smoking and biological aging has been less clear. Yet, a new study from an international team of investigators led by scientists at Insilico Medicine may change how smoking is evaluated at the biochemical level. "In this study, we demonstrate for the first time that smoking status can be predicted using blood biochemistry and cell count results and the recent advances in artificial intelligence (AI)," the study authors explained.